Literature DB >> 9891698

Gastrointestinal manifestations of scleroderma.

S Rose1, M A Young, J C Reynolds.   

Abstract

Gastrointestinal involvement is commonly found in scleroderma. Gastrointestinal symptoms may be the presenting symptoms for the diagnosis and may precede the actual diagnosis by months to years. The esophagus is the most frequently affected, but functional problems of the anorectum, small bowel, colon, and stomach may occur. The pathophysiologic mechanism appears to be one of smooth muscle atrophy and, to a lesser degree, fibrosis. These changes result in gastrointestinal motility disturbances and may cause GERD, pseudo-obstruction, bacterial overgrowth, and defecatory disorders. Malnutrition may be a serious consequence. The evaluation of a particular symptom in a patient with scleroderma may lead to treatment strategies that improve the patient's sense of well-being and quality of life.

Entities:  

Mesh:

Year:  1998        PMID: 9891698     DOI: 10.1016/s0889-8553(05)70021-2

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  21 in total

1.  Small Intestinal Bacterial Overgrowth Syndrome.

Authors:  Jeffery S. Meyers; Eli D. Ehrenpreis; Robert M. Craig
Journal:  Curr Treat Options Gastroenterol       Date:  2001-02

2.  Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment.

Authors:  Virmeet V. Singh; Phillip P. Toskes
Journal:  Curr Treat Options Gastroenterol       Date:  2004-02

3.  Autoantibody profile in systemic sclerosis as a marker for esophageal and other organ involvement in Turkish populations.

Authors:  Nurten Savas; Ulku Dagli; Esin Ertugrul; Sedef Kuran; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

4.  Management of gastrointestinal involvement in scleroderma.

Authors:  Vivek Nagaraja; Zsuzsanna H McMahan; Terri Getzug; Dinesh Khanna
Journal:  Curr Treatm Opt Rheumatol       Date:  2015-03-01

Review 5.  Functional autoantibodies in systemic sclerosis pathogenesis.

Authors:  Angela Kill; Gabriela Riemekasten
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

6.  Gastrointestinal manifestations in Hungarian scleroderma patients.

Authors:  Szilvia Szamosi; Zoltán Szekanecz; Gabriella Szucs
Journal:  Rheumatol Int       Date:  2006-06-13       Impact factor: 2.631

7.  Risk factors for body composition abnormalities in systemic sclerosis.

Authors:  Thais F Marighela; Patrícia de S Genaro; Marcelo M Pinheiro; Vera L Szejnfeld; Cristiane Kayser
Journal:  Clin Rheumatol       Date:  2013-04-03       Impact factor: 2.980

Review 8.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

9.  Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Med Res Arch       Date:  2020-10-29

10.  [Medico-legal assessment of systemic sclerosis].

Authors:  M Graninger
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.